373 filings
Page 10 of 19
8-K
8ygc0 6teisoylp
8 Apr 13
Departure of Directors or Certain Officers
12:00am
8-K
lkwzyao0x1cx
8 Mar 13
Departure of Directors or Certain Officers
12:00am
8-K
94pu hjei7n
25 Jan 13
Departure of Directors or Certain Officers
12:00am
8-K
pvsyu3pdxfe1whnes
24 Jan 13
Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2012 Financial Results
12:00am
8-K
dsfnyg10d3qq0z
24 Oct 12
Bristol-Myers Squibb Reports Third Quarter 2012 Financial Results
12:00am
8-K
tl2wa mdx5g
3 Oct 12
Sanofi and Bristol-Myers Squibb Announce Restructuring of Alliance Agreement
12:00am
8-K
5un5n5xikg j9xh4
24 Aug 12
Bristol-Myers Squibb Discontinues Development of BMS-986094, an Investigational NS5B Nucleotide for the Treatment of Hepatitis C
12:00am
8-K
t2lc2owecjguyec3 9yb
10 Aug 12
Completion of Acquisition or Disposition of Assets
12:00am
8-K
ceay1f54p8mi9z
3 Aug 12
Bristol-Myers Squibb Suspends Administration of Study Drug in Clinical Trial of Investigational NS5B Nucleotide for the Treatment of Hepatitis C
12:00am
8-K
xporiuqegn8xw37et6
31 Jul 12
Entry into a Material Definitive Agreement
12:00am
8-K
zqeg3dko7tcjc
25 Jul 12
Planned Acquisition of Amylin Expected to Add Two Marketed GLP-1 Agonists to Our Diabetes Franchise and Our Alliance with AstraZeneca
12:00am
8-K
9bkxv5zfdp0w4jc
3 Jul 12
Entry into a Material Definitive Agreement
12:00am
8-K
pu1t 03dmqykodg
7 May 12
Departure of Directors or Certain Officers
12:00am
8-K
t8l5n7zb
26 Apr 12
Bristol-Myers Squibb Delivers a Solid First Quarter with Strong Operating Results and Key R&D Milestones
12:00am
8-K
44gvq13v1n51v4rwm
8 Mar 12
Other Events
12:00am
8-K
8zw u79hy
13 Feb 12
Other Events
12:00am
8-K
0wnmmyd6vni
26 Jan 12
Net Sales Rise 7% to $5.5 Billion in Fourth Quarter
12:00am
8-K
g7xn9m
24 Jan 12
Bristol-Myers Squibb Names Gerald L. Storch to Board of Directors
12:00am
8-K
7dyceii0nn sag
9 Jan 12
Bristol-Myers Squibb to Acquire Inhibitex
12:00am
8-K
61yvlk
27 Oct 11
Bristol-Myers Squibb Delivers Strong Third Quarter with Important Clinical Data, Solid Operating Results and Continued Focus on Business Development
12:00am